WO2001051024A3 - Kit zur implantation enthaltend eine trägerphase und ein lösemittel - Google Patents

Kit zur implantation enthaltend eine trägerphase und ein lösemittel Download PDF

Info

Publication number
WO2001051024A3
WO2001051024A3 PCT/DE2001/000179 DE0100179W WO0151024A3 WO 2001051024 A3 WO2001051024 A3 WO 2001051024A3 DE 0100179 W DE0100179 W DE 0100179W WO 0151024 A3 WO0151024 A3 WO 0151024A3
Authority
WO
WIPO (PCT)
Prior art keywords
solvent
support phase
preparation
kit
implantation kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2001/000179
Other languages
English (en)
French (fr)
Other versions
WO2001051024A2 (de
Inventor
Roland Bodmeier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000101682 external-priority patent/DE10001682A1/de
Priority claimed from DE2000101683 external-priority patent/DE10001683A1/de
Priority to DK01909488T priority Critical patent/DK1248596T3/da
Application filed by Individual filed Critical Individual
Priority to AU2001237221A priority patent/AU2001237221A1/en
Priority to DE10190041T priority patent/DE10190041D2/de
Priority to EP01909488A priority patent/EP1248596B1/de
Priority to DE50112157T priority patent/DE50112157D1/de
Publication of WO2001051024A2 publication Critical patent/WO2001051024A2/de
Publication of WO2001051024A3 publication Critical patent/WO2001051024A3/de
Priority to US10/192,575 priority patent/US7927618B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)

Abstract

Beschrieben werden Kits zur Herstellung einer Zubereitung, welche eine Trägerphase enthält, die im Körper, auf dem Körper oder unter physiologischen Umgebungsbedingungen ein Implantat oder Partikel bildet, wobei die Trägerphase zumindest ein Trägermaterial und ein Lösemittel enthält, dadurch gekennzeichnet, dass das Trägermaterial und das Lösungsmittel im Kit getrennt voneinander vorliegen, sowie Zubereitungen hergestellt aus diesem Kit und Verfahren zur Herstellung des Kits und der Zubereitung.
PCT/DE2001/000179 2000-01-11 2001-01-11 Kit zur implantation enthaltend eine trägerphase und ein lösemittel Ceased WO2001051024A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE50112157T DE50112157D1 (de) 2000-01-11 2001-01-11 Kit zur implantation enthaltend eine trägerphase und ein lösungsmittel
EP01909488A EP1248596B1 (de) 2000-01-11 2001-01-11 Kit zur implantation enthaltend eine trägerphase und ein lösungsmittel
DK01909488T DK1248596T3 (da) 2000-01-11 2001-01-11 Implantater, partikler
AU2001237221A AU2001237221A1 (en) 2000-01-11 2001-01-11 Implants, particles
DE10190041T DE10190041D2 (de) 2000-01-11 2001-01-11 Implantate, Partikel
US10/192,575 US7927618B2 (en) 2000-01-11 2002-07-10 Implants, particles

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE2000101682 DE10001682A1 (de) 2000-01-11 2000-01-11 Partikel/Implantate
DE10001682.0 2000-01-11
DE10001683.9 2000-01-11
DE2000101683 DE10001683A1 (de) 2000-01-11 2000-01-11 Implantate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/192,575 Continuation US7927618B2 (en) 2000-01-11 2002-07-10 Implants, particles

Publications (2)

Publication Number Publication Date
WO2001051024A2 WO2001051024A2 (de) 2001-07-19
WO2001051024A3 true WO2001051024A3 (de) 2001-12-27

Family

ID=26003884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2001/000179 Ceased WO2001051024A2 (de) 2000-01-11 2001-01-11 Kit zur implantation enthaltend eine trägerphase und ein lösemittel

Country Status (9)

Country Link
US (1) US7927618B2 (de)
EP (1) EP1248596B1 (de)
AT (1) ATE355824T1 (de)
AU (1) AU2001237221A1 (de)
DE (2) DE10190041D2 (de)
DK (1) DK1248596T3 (de)
ES (1) ES2283394T3 (de)
PT (1) PT1248596E (de)
WO (1) WO2001051024A2 (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846072B2 (en) 2004-09-17 2014-09-30 Durect Corporation Controlled delivery system
US8945614B2 (en) 2002-12-13 2015-02-03 Durect Corporation Oral drug delivery system
US8956644B2 (en) 2006-11-03 2015-02-17 Durect Corporation Transdermal delivery systems
US9555113B2 (en) 2013-03-15 2017-01-31 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US9592204B2 (en) 2007-12-06 2017-03-14 Durect Corporation Oral pharmaceutical dosage forms

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT996426E (pt) * 1997-06-05 2007-06-18 Bertex Pharma Gmbh Sistema multifásico
US6599441B1 (en) * 2000-07-18 2003-07-29 Emerald Biostructures, Inc. Crystallization solutions
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
WO2004004671A1 (en) * 2002-07-02 2004-01-15 Procyte Corporation Compositions containing peptide copper complexes and soft tissue fillers
GB0305941D0 (en) * 2003-03-14 2003-04-23 Camurus Ab Composition
US7169405B2 (en) * 2003-08-06 2007-01-30 Warsaw Orthopedic, Inc. Methods and devices for the treatment of intervertebral discs
US7275640B2 (en) * 2004-02-05 2007-10-02 Boston Scientific Scimed, Inc. Packaging for imparting anti-microbial properties to a medical device
US20050186240A1 (en) * 2004-02-23 2005-08-25 Ringeisen Timothy A. Gel suitable for implantation and delivery system
ATE372772T1 (de) * 2004-07-13 2007-09-15 Schering Oy Retardiertes freigabesystem mit kontrollierter initialabgabe
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
WO2006041942A2 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
DE102005025640A1 (de) * 2005-06-03 2006-12-07 Scienion Ag Mikrodispenser und zugehöriges Betriebsverfahren
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20070074980A1 (en) * 2005-09-02 2007-04-05 Bankoski Brian R Implant rehydration packages and methods of use
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
EP3403681A1 (de) 2008-05-30 2018-11-21 Allergan, Inc. Injektionsvorrichtung für weichgewebsaufbauende füllstoffe, bioaktive mittel und andere biokompatible materialien in flüssiger oder gelform
US8252228B1 (en) * 2008-10-13 2012-08-28 Abbott Cardiovascular Systems Inc. Methods for sterilizing carriers for treatment of a kidney
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
SI3187219T1 (sl) 2008-12-02 2020-09-30 Allergan, Inc. Injekcijska naprava
US8361012B2 (en) * 2009-07-14 2013-01-29 Southwest Research Institute Dry to wet injector
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
ES2589106T3 (es) * 2010-05-31 2016-11-10 Laboratorios Farmaceuticos Rovi, S.A. Composición inyectable antipsicótica de liberación controlada
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
SI2394663T1 (sl) * 2010-05-31 2022-02-28 Laboratorios Farmaceuticos Rovi, S.A. Sestave za injicirane biološko razgradljive vsadke in situ
WO2011161531A1 (en) 2010-06-24 2011-12-29 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
EP2986278A1 (de) 2013-03-11 2016-02-24 DURECT Corporation Injizierbare zusammensetzung mit gesteuerter freisetzung mit einem hochviskosen flüssigen träger
US20140350518A1 (en) 2013-05-23 2014-11-27 Allergan, Inc. Syringe extrusion accessory
US9757330B2 (en) 2013-10-18 2017-09-12 Industrial Technology Research Institute Recipe for in-situ gel, and implant, drug delivery system formed thereby
US10029048B2 (en) 2014-05-13 2018-07-24 Allergan, Inc. High force injection devices
US10226585B2 (en) 2014-10-01 2019-03-12 Allergan, Inc. Devices for injection and dosing
DE102014117532A1 (de) 2014-11-28 2016-06-02 Eberhard Karls Universität Tübingen Medizinische Fakultät Antimikrobielle photodynamische Therapie
BR112017019272A2 (pt) 2015-03-10 2018-05-02 Allergan Pharmaceuticals Holdings Ireland Unlimited Company injetor de múltiplas agulhas
US10596321B2 (en) 2016-04-08 2020-03-24 Allergan, Inc. Aspiration and injection device
US20170290771A1 (en) * 2016-04-12 2017-10-12 Southern Research Institute Biodegradable in situ forming microparticles and methods for producing the same
US12274794B2 (en) 2016-07-06 2025-04-15 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
USD867582S1 (en) 2017-03-24 2019-11-19 Allergan, Inc. Syringe device
WO2019125358A1 (en) * 2017-12-18 2019-06-27 Foresee Pharmaceuticals Pharmaceutical compositions having a selected release duration
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
JP7506679B2 (ja) 2018-10-29 2024-06-26 フラウンホーファー－ゲゼルシャフト・ツール・フェルデルング・デル・アンゲヴァンテン・フォルシュング・アインゲトラーゲネル・フェライン 持続性活性を有するテトラサイクリン複合体
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法
US12594236B2 (en) 2021-07-16 2026-04-07 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
EP4527389A4 (de) 2022-05-18 2026-05-06 Farm Rovi Lab Sa Injizierbare zusammensetzungen mit verlängerter freisetzung zur verwendung bei der behandlung mit risperidon zusammen mit cyp2d6-enzymhemmern

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5081156A (en) * 1983-10-14 1992-01-14 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release preparation
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
WO1998055100A1 (de) * 1997-06-05 1998-12-10 Roland Bodmeier Multiphasensystem

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188373A (en) 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4865585A (en) * 1981-07-13 1989-09-12 Alza Corporation Method of administering drug by using cell comprising drug
US4454110A (en) 1982-05-24 1984-06-12 Forsyth Dental Infirmary For Children Self-gelling liquid composition for topical application in the oral cavity
EP0190833B1 (de) 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Verfahren zur Herstellung von Mikrokapseln
US5938654A (en) * 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5632727A (en) * 1988-10-03 1997-05-27 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US5725491A (en) 1988-10-03 1998-03-10 Atrix Laboratories, Inc. Method of forming a biodegradable film dressing on tissue
US5324520A (en) 1988-12-19 1994-06-28 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
US5487897A (en) 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
US5336180A (en) * 1990-04-24 1994-08-09 Science Incorporated Closed drug delivery system
ZA918526B (en) 1990-10-30 1992-08-26 Alza Corp Drug delivery system and method
AU652022B2 (en) 1991-02-12 1994-08-11 C.R. Bard Inc. Injectable medical device
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
EP0560014A1 (de) 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biologisch abbaubarer Wundverband in Form eines Sprühfilms und Verfahren zu seiner Herstellung
US5681873A (en) 1993-10-14 1997-10-28 Atrix Laboratories, Inc. Biodegradable polymeric composition
US5452648A (en) * 1993-10-21 1995-09-26 Hobart Corporation Screen box for a pasta cooker
EP2283821A1 (de) 1993-11-19 2011-02-16 Alkermes, Inc. Herstellung biodegradierbarer Mikroteilchen, die ein biologisch aktives Mittel enthalten
ES2258495T3 (es) 1994-04-08 2006-09-01 Qlt Usa, Inc. Composiciones de administracion liquida de farmacos.
AU1999995A (en) 1994-04-08 1995-11-10 Atrix Laboratories, Inc. An adjunctive polymer system for use with medical device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5722950A (en) 1995-06-07 1998-03-03 Atrix Laboratories, Inc. Method for remote delivery of an aerosolized liquid
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
AU724089B2 (en) * 1996-12-05 2000-09-14 Idego Aps Sensor laminates and multi-sectioned fluid delivery devices for detecting by immunoassay target molecules in biological fluids
US6796966B2 (en) * 1997-10-15 2004-09-28 Jeffrey E. Thomas Apparatus, and kits for preventing of alleviating vasoconstriction or vasospasm in a mammal
US20020055708A1 (en) * 1999-09-24 2002-05-09 Peterson Kenneth R. Coupling syringe system and methods for obtaining a mixed composition
US8226598B2 (en) * 1999-09-24 2012-07-24 Tolmar Therapeutics, Inc. Coupling syringe system and methods for obtaining a mixed composition
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6981963B2 (en) * 2001-03-13 2006-01-03 Mdc Investment Holdings, Inc. Pre-filled safety diluent injector
US6663596B2 (en) * 2001-08-13 2003-12-16 Scimed Life Systems, Inc. Delivering material to a patient

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5081156A (en) * 1983-10-14 1992-01-14 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release preparation
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
WO1998055100A1 (de) * 1997-06-05 1998-12-10 Roland Bodmeier Multiphasensystem

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945614B2 (en) 2002-12-13 2015-02-03 Durect Corporation Oral drug delivery system
US8951556B2 (en) 2002-12-13 2015-02-10 Durect Corporation Oral drug delivery system
US8974821B2 (en) 2002-12-13 2015-03-10 Durect Corporation Oral drug delivery system
US8846072B2 (en) 2004-09-17 2014-09-30 Durect Corporation Controlled delivery system
US8956644B2 (en) 2006-11-03 2015-02-17 Durect Corporation Transdermal delivery systems
US9592204B2 (en) 2007-12-06 2017-03-14 Durect Corporation Oral pharmaceutical dosage forms
US9555113B2 (en) 2013-03-15 2017-01-31 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability

Also Published As

Publication number Publication date
EP1248596B1 (de) 2007-03-07
EP1248596A2 (de) 2002-10-16
AU2001237221A1 (en) 2001-07-24
US20040010224A1 (en) 2004-01-15
ATE355824T1 (de) 2007-03-15
PT1248596E (pt) 2007-06-21
ES2283394T3 (es) 2007-11-01
DK1248596T3 (da) 2007-07-02
DE10190041D2 (de) 2002-12-05
WO2001051024A2 (de) 2001-07-19
DE50112157D1 (de) 2007-04-19
US7927618B2 (en) 2011-04-19

Similar Documents

Publication Publication Date Title
AU2001237221A1 (en) Implants, particles
AU6094999A (en) Accommodative intraocular implant
AU2624901A (en) Methods for manufacturing skeletal implants
WO2001034064A3 (en) Micro structure stent configurations
WO2003011184A8 (en) Adventitial fabric reinforced porous prosthetic graft
AU2003257180A1 (en) Biocompatible phase invertable proteinaceous compostions and methods for making and using the same
ZA987540B (en) Process for the preparation of stanol esters, and use thereof.
AU2002332081A1 (en) Method, tool, and system for deploying an implant into the body
AU5801199A (en) Bottom or top jumpered foldable electronic assembly, and method for manufacture
WO2001070197A3 (en) Method for preparing high pressure/high shear dispersions containing physiologically active ingredients
AU2884197A (en) Expansible bioprosthetic valve stent
HK1039342A1 (zh) 結締組織生長因子(ctgf)及使用的方法
AU8906198A (en) Template for designing human seating accomodations
AU2001215528A1 (en) Base materials for tissue regeneration, transplant materials and process for producing the same
AU5686400A (en) Method for producing quickly decomposable solid pharmaceutical preparations
WO1999025843A3 (en) Human checkpoint kinase, hcds1, compositions and methods
AU3425700A (en) Non-ribosomal peptide synthetases, method for producing same and the use thereof
EP0856512A3 (de) 1-Deoxy-Paclitaxele, Herstellungsmethode und pharmazeutische Anwendung
AU8451498A (en) Methods for the preparation of artificial cellular tissue
AU3868299A (en) Flavored oil-in-vinegar microemulsion concentrates, method for preparing the same
AU2001266274A1 (en) Assay techniques based on growth stage dependent expression inc. elegans
AU2001291871A1 (en) Method for the isomerisation of allyl alcohols
AU2055199A (en) Artificial fur and method for its manufacture
AU6866500A (en) Chromone derivatives, process for the preparation of the same and uses thereof
EP0861838A3 (de) Verfahren und Intermediate zur Herstellung von Cryptophycinverbindungen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001909488

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001909488

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001909488

Country of ref document: EP